Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
نویسندگان
چکیده
منابع مشابه
Biomarkers in amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis (ALS; motor neuron disease) is a relentlessly progressive disorder. After half a century of trials, only one drug with modest disease-modifying potency--riluzole--has been developed. The diagnosis of this disorder is still clinical and there is a pronounced delay between the onset of symptoms and diagnosis, possibly beyond the therapeutic window. Bedside quantifica...
متن کاملPrognostic factors in C9orf72 amyotrophic lateral sclerosis.
310 Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLEPD study M J Firbank, A J Yarnall, R A Lawson, G W Duncan, T K Khoo, G S Petrides, J T O’Brien, R A Barker, R J Maxwell, D J Brooks, D J Burn 317 ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease A Antonini, P Barone, U Bonuccelli, K Annoni, M Asgharnejad,...
متن کاملAmyotrophic lateral sclerosis: considerations on diagnostic criteria.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder, compromising the motor neuron, characterized by progressive muscle weakness, with reserved prognosis. The diagnosis is based on inclusion and exclusion clinical criteria, since there is no specific confirmation test. The objective of this research is to critically examine the main diagnosis instrument - El Escorial revisited, ...
متن کاملSmads as muscle biomarkers in amyotrophic lateral sclerosis
OBJECTIVE To identify molecular signatures in muscle from patients with amyotrophic lateral sclerosis (ALS) that could provide insight into the disease process and serve as biomarkers. METHODS RNA sequencing was performed on ALS and control muscle samples to identify Smad family members as potential markers of disease. Validation studies were performed in a cohort of 27 ALS patients and 33 co...
متن کاملEnsuring continued progress in biomarkers for amyotrophic lateral sclerosis
Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as wel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Neurology
سال: 2017
ISSN: 2168-6149
DOI: 10.1001/jamaneurol.2016.5398